Neobiosis

Executive Summary

Neobiosis is a US-based biotechnology company specializing in the development and manufacturing of regenerative therapies derived from perinatal tissues such as amniotic fluid, placenta, and umbilical cord. Founded in 2015 and headquartered in Tampa, Florida, the company utilizes proprietary technology to extract cells, extracellular vesicles, and matrix components. Neobiosis operates both as a Contract Development and Manufacturing Organization (CDMO) serving external clients and as an internal research and development engine advancing its own pipeline of regenerative medicine products. The company's stage is listed as "Approved," indicating it has at least one commercialized product, positioning it as a revenue-generating entity in the competitive biologics space. With a focus on the rapidly growing regenerative medicine market, Neobiosis is well-positioned to benefit from increasing demand for tissue-derived biologics. Its dual CDMO and proprietary product strategy provides diversified revenue streams and potential for high-margin growth. The company's technology platform has applications across wound healing, orthopedics, and surgical procedures. Key catalysts include expansion of its CDMO client base, advancement of internal pipeline candidates, and potential capacity expansion to meet growing demand. The company's private status limits public visibility, but its approved product status suggests commercial traction and a scalable business model.

Upcoming Catalysts (preview)

• Q4 2026New CDMO partnership with a top-10 pharmaceutical company60% success
• Q2 2027FDA clearance of a new product from internal pipeline40% success
• Q3 2026Expansion of manufacturing capacity to support growing demand75% success